2005
Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study
Modi W, Scott K, Goedert J, Vlahov D, Buchbinder S, Detels R, Donfield S, O'Brien S, Winkler C. Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study. Genes & Immunity 2005, 6: 691-698. PMID: 16177829, DOI: 10.1038/sj.gene.6364258.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAllelesBlack or African AmericanChemokine CXCL12Chemokines, CXCChildCohort StudiesDisease ProgressionFemaleGene FrequencyHaplotypesHIV InfectionsHIV-1HumansLongitudinal StudiesMaleOdds RatioPolymorphism, Single NucleotideRisk FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsSDF-1 geneCohort studySingle nucleotide polymorphismsAfrican AmericansOnly natural ligandSingle disease outcomesX4 HIV-1HIV-1 infectionAIDS Cohort StudyRisk of infectionMACS cohortDisease outcomeHIV-1Epidemiological studiesSDF-1Significant associationChemokine genesInfectionRs1801157Natural ligandProgressionHaplotype analysisCommon haplotypeCXCR4Cohort
2004
Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users
Tun W, Gange S, Vlahov D, Strathdee S, Celentano D. Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. Clinical Infectious Diseases 2004, 38: 1167-1174. PMID: 15095224, DOI: 10.1086/383033.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyHAART initiationCell countAntiretroviral therapyDrug usersSexual intercourseRisk reduction counselingHuman immunodeficiency virusLarge cohort studyDrug injection behaviorInjection of drugsUnprotected sexual intercourseSemiannual visitsReduction counselingCohort studyHIV infectionHIV serostatusImmunodeficiency virusImmunologic responseNeedle sharingBlood samplesSurvival analysisRisk behaviorsCD4
2003
Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection
Royal W, Vlahov D, Lyles C, Gajewski C. Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases 2003, 37: s427-s432. PMID: 14648459, DOI: 10.1086/377554.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionDrug usersSeronegative control subjectsRetinoic acidDevelopment of HIVInjection drug usersTumor necrosis factorNervous system diseasesLevels of retinolMononuclear cell lineNeurological disease riskTrans retinoic acidDrugs of abuseRetinoid administrationClinical outcomesRetinol-binding proteinImmunomodulatory effectsControl subjectsNecrosis factorSystem diseasesNeurological diseasesHIVDisease riskEffects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
2002
Regional variation in CCR5-Δ32 gene distribution among women from the US HIV Epidemiology Research Study (HERS)
Downer M, Hodge T, Smith D, Qari S, Schuman P, Mayer K, Klein R, Vlahov D, Gardner L, McNicholl J. Regional variation in CCR5-Δ32 gene distribution among women from the US HIV Epidemiology Research Study (HERS). Genes & Immunity 2002, 3: 295-298. PMID: 12140749, DOI: 10.1038/sj.gene.6363884.Peer-Reviewed Original ResearchConceptsHIV Epidemiology Research StudyRace/ethnicityHIV-1HIV Epidemiologic Research StudyAfrican AmericansCCR5-Δ32 genotypeHIV-1 transmissionEpidemiologic research studiesHost genetic factorsHispanic/LatinaBlack/African AmericanUninfected womenAA womenUS womenCCR5-Δ32US populationWhite womenFrequency of heterozygotesWomenGenetic factorsDistributions of heterozygotesRegional variationResearch studies
2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S, Coutinho R, Eugen-Olsen J, Gallart T, Katzenstein T, Kostrikis L, Kuipers H, Louie L, Mallal S, Margolick J, Martinez O, Meyer L, Michael N, Operskalski E, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Stewart G, Theodorou I, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J, O'Brien T. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Annals Of Internal Medicine 2001, 135: 782-95. PMID: 11694103, DOI: 10.7326/0003-4819-135-9-200111060-00008.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCCR2-64I alleleHIV-1 RNA levelsHIV-1 disease progressionDevelopment of AIDSIndividual patient dataCCR5-Delta32Decreased riskDisease progressionProtective effectLower HIV-1 RNA levelsRNA levelsProspective cohort studyCase-control studyClear protective effectStrong protective effectChemokine receptor genesRandom-effects modelCCR2-64ICohort studyStudy entryCertain chemokinesAIDSInfectionProgressionImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. PMID: 11317071, DOI: 10.1097/00126334-200104010-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBaltimoreBody Mass IndexCD4 Lymphocyte CountChronic DiseaseFemaleHemoglobinsHIV InfectionsHIV-1HumansLongitudinal StudiesMaleMultivariate AnalysisPrevalenceSex FactorsSubstance Abuse, IntravenousViral LoadConceptsInjection drug usersPlasma HIV loadActive antiretroviral therapyAntiretroviral therapyHIV loadOpportunistic infectionsCopies/Mean decreaseDrug usersHIV-positive injection drug usersPotent antiretroviral therapyImprovement of anemiaBody mass indexIncrease of hemoglobinAntiretroviral medicationsHIV infectionMass indexControl subjectsOverall prevalenceChronic diseasesAnemiaNutritional statusMean increaseMultivariate analysisHAARTInitial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10
Shin H, Winkler C, Stephens J, Bream J, Young H, Goedert J, O'Brien T, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien S, Smith M. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 14467-14472. PMID: 11121048, PMCID: PMC18942, DOI: 10.1073/pnas.97.26.14467.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-1 replicationTranscription factor recognition sequencePromoter allelesLong-term nonprogressorsHIV-1 pathogenesisSingle nucleotide polymorphic variantsOnset of AIDSMacrophages/monocytesNuclear transcription factorSignificant genotype associationsIL10 promoter regionShort tandem repeat polymorphismsTranscription factorsPromoter regionRecognition sequenceIL10 productionInflammatory cytokinesCell cytokinesAIDS cohortC genotypeLymphoid cellsPromoter genotypeGenetic restrictionLymphocyte replicationShort tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes
Shrestha S, Strathdee S, Brahmbhatt H, Farzadegan H, Vlahov D, Smith M. Short tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes. AIDS 2000, 14: 1507-1513. PMID: 10983637, DOI: 10.1097/00002030-200007280-00006.Peer-Reviewed Original Research
1999
The Effect of Drug-Injection Behavior on Genetic Evolution of HIV-1
Carneiro M, Yu X, Lyles C, Templeton A, Weisstein A, Safaeian M, Farzadegan H, Vlahov D, Markham R. The Effect of Drug-Injection Behavior on Genetic Evolution of HIV-1. The Journal Of Infectious Diseases 1999, 180: 1025-1032. PMID: 10479127, DOI: 10.1086/315044.Peer-Reviewed Original ResearchLongitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load
Lyles C, Dorrucci M, Vlahov D, Pezzotti P, Angarano G, Sinicco A, Alberici F, Alcorn T, Vella S, Rezza G. Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. The Journal Of Infectious Diseases 1999, 180: 1018-1024. PMID: 10479126, DOI: 10.1086/314980.Peer-Reviewed Original ResearchConceptsHIV-1 loadVirus loadHuman immunodeficiency virus type 1 (HIV-1) loadHuman immunodeficiency virus type 1 (HIV-1) seroconvertersCD4 cells/microL.Low CD4 cell countsItalian Seroconversion StudyCD4 cell countCells/microL.Injection drug useCourse of diseaseReverse transcriptase-polymerase chain reactionHigh virus loadTranscriptase-polymerase chain reactionClinical AIDSMale sexProspective studyDisease progressionSeroconversion StudyCell countDrug useSustained increaseSeroconversionAIDSFrozen serumSex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling T, Lyles C, Vlahov D, Astemborski J, Margolick J, Quinn T. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. The Journal Of Infectious Diseases 1999, 180: 666-672. PMID: 10438353, DOI: 10.1086/314967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 RNA levelsHIV-1 seroconvertersSex differencesCopies/mLHIV-1 pathogenesisInjection drug usersCase-control studyTime of seroconversionCross-sectional studyCourse of infectionMale patientsRapid progressorsFemale patientsCopies/Drug usersMale controlsVirus levelsPatientsRNA levelsSeroconvertersWomenMenNonprogressorsSeroconversionProgressorsReduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation.
Dean M, Jacobson L, McFarlane G, Margolick J, Jenkins F, Howard O, Dong H, Goedert J, Buchbinder S, Gomperts E, Vlahov D, Oppenheim J, O'Brien S, Carrington M. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Research 1999, 59: 3561-4. PMID: 10446961.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsB-LymphocytesCase-Control StudiesChemokine CCL5Cohort StudiesGene FrequencyGenetic Predisposition to DiseaseHIV-1HumansLymphoma, AIDS-RelatedMalePoint MutationReceptors, CCR5RiskSarcoma, KaposiSequence DeletionTetradecanoylphorbol AcetateWhite PeopleConceptsNon-Hodgkin lymphomaB cellsAIDS lymphomasCCR5 geneRisk of NHLMulticenter AIDS Cohort StudyCCR5 ligand RANTEST-cell declineAIDS Cohort StudyCCR5-Delta32 alleleB-cell lymphomaCase-control analysisCCR5-Delta32 mutationChemokine receptor genesCCR5 chemokine receptor geneTime of infectionLigand RANTESTime AIDSCohort studyOpportunistic infectionsAIDS patientsCommon malignancyKaposi's sarcomaNHL casesProliferative responseComparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load
Rompalo A, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg S, Warren D, Farzadegan H, Vlahov D, Smith D. Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 448-454. PMID: 10225226, DOI: 10.1097/00042560-199904150-00006.Peer-Reviewed Original ResearchConceptsHIV-1 viral loadPlasma viral loadBody mass indexHIV-1 plasma viral loadOral hairy leukoplakiaInjection drug useViral loadInjection drug usersRisk groupsHIV infectionCell countDrug useHairy leukoplakiaCells/Clinical manifestationsHeterosexual contactMedian HIV-1 viral loadPlasma HIV-1 viral loadUndetectable HIV-1 viral loadPlasma viral load levelsHIV viral loadIntravenous drug useViral load levelsPopulation of HIVPrevalence of HIVCell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, Farzadegan H. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. European Journal Of Epidemiology 1999, 15: 99-108. PMID: 10204638, DOI: 10.1023/a:1007556327269.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionFemaleFollow-Up StudiesHIV InfectionsHIV-1Homosexuality, MaleHumansImmunocompromised HostLeukocytes, MononuclearMalePredictive Value of TestsProportional Hazards ModelsRisk FactorsSubstance Abuse, IntravenousSurvival AnalysisSurvival RateViral LoadViremiaConceptsHIV-1 viral loadViral loadHomosexual menRisk groupsHIV-1Relative hazardDrug usersPeripheral blood mononuclear cellsMicroculture techniqueBlood mononuclear cellsInjection drug usersHIV-1 progressionInitial CD4Clinical progressionMononuclear cellsNegative culturesPredictive valueSurvival analysisBacterial infectionsTotal participantsAIDSProgressionInfectious unitsCells/DeathCriteria for assessing cutaneous anergy in women with or at risk for HIV infection
Klein R, Flanigan T, Schuman P, Smith D, Vlahov D, Group* F. Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. Journal Of Allergy And Clinical Immunology 1999, 103: 93-98. PMID: 9893191, DOI: 10.1016/s0091-6749(99)70531-2.Peer-Reviewed Original ResearchConceptsHIV statusCutaneous anergyHIV infectionTetanus antigensTuberculin reactionLevel of immunodeficiencyHIV-seronegative womenPositive tuberculin reactionAcademic medical centerAnergy testingLow CD4Seronegative subjectsHIV-seronegativeMumps antigenSeropositive subjectsSeropositive womenHIV-seropositiveLymphocyte levelsRisk womenTuberculin antigenTetanus toxoidCutaneous testingMedical CenterClinical utilityAntigen combinations
1998
Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5
Martin M, Dean M, Smith M, Winkler C, Gerrard B, Michael N, Lee B, Doms R, Margolick J, Buchbinder S, Goedert J, O'Brien T, Hilgartner M, Vlahov D, O'Brien S, Carrington M. Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5. Science 1998, 282: 1907-1911. PMID: 9836644, DOI: 10.1126/science.282.5395.1907.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAllelesChemokine CXCL12Chemokines, CXCCohort StudiesDisease ProgressionGenes, DominantGenes, RecessiveGenetic Predisposition to DiseaseGenotypeHaplotypesHeterozygoteHIV InfectionsHIV-1HomozygoteHumansPromoter Regions, GeneticProportional Hazards ModelsReceptors, CCR2Receptors, CCR5Receptors, ChemokineReceptors, CytokineRisk FactorsSurvival RateConceptsAIDS progressionCell-surface chemokine receptor moleculeCCR5 regulatory regionsChemokine receptor moleculesPercent of patientsAIDS disease progressionHIV-1 infectionCohort of peopleMacrophage-tropic strainsAIDS restriction genesDistinct regulatory influencesCCR2-64IPrincipal coreceptorImmunodeficiency syndromeCCR5-Delta32Genetic epidemiologic analysisDisease progressionHuman immunodeficiencySDF1-3'APromoter genotypeCCR5 geneInfected individualsEpidemiologic analysisHost factorsProgressionComparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups
Lyles C, Vlahov D, Farzadegan H, Astemborski J, Margolick J, Masters B, Schroeder J, Quinn T. Comparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups. Journal Of Clinical Microbiology 1998, 36: 3647-3652. PMID: 9817889, PMCID: PMC105256, DOI: 10.1128/jcm.36.12.3647-3652.1998.Peer-Reviewed Original ResearchConceptsInfectious viral loadInjection drug usersHIV RNA levelsHIV RNA loadViral loadRisk groupsRNA loadViral burdenHuman immunodeficiency virus type 1 (HIV-1) loadHomosexual menPlasma HIV RNA levelsMale injection drug usersFemale injection drug usersHuman immunodeficiency virus type 1Peripheral blood mononuclear cellsImmunodeficiency virus type 1RNA levelsBlood mononuclear cellsHIV risk groupViral RNA loadVirus type 1HIV loadMononuclear cellsDrug usersCell countSex differences in HIV-1 viral load and progression to AIDS
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, Quinn T, Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1998, 352: 1510-1514. PMID: 9820299, DOI: 10.1016/s0140-6736(98)02372-1.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell countProportional hazards modelBranched-chain DNAViral loadQuantitative microcultureReverse transcriptase-PCRPlasma HIV-1 RNA measurementsCell countHIV-1 RNA measurementsUnivariate proportional hazard modelHIV-1 viral loadSame viral loadViral load associationsVisit 3 yearsHIV-1 loadViral load measurementsAntiretroviral therapyAntiretroviral treatmentBaseline visitCommunity clinicsObservational studyHIV-1Current recommendationsHigh risk